📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-01 17:34
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Promoters Disclose Massive Stake Sale in Kronox Lab Sciences
Kronox Lab Sciences has submitted disclosures under SEBI PIT Regulations regarding significant equity stake sales by three key individuals/promoters. Jogindersingh Jaswal disclosed the sale of 97,96,400 equity shares (~23.09% of total paid-up equity). Concurrently, Ketan Ramani disclosed the sale of 97,96,400 shares (~23.09%), and Pritesh Ramani reported selling 67,11,200 shares (~18.09%). This represents a massive cumulative offloading of ownership, drastically reducing historical promoter holding from 74.21%.
Confidence: HIGH
What changedKey insiders/promoters (Jogindersingh Jaswal, Ketan Ramani, Pritesh Ramani) offloaded major stakes totaling over 64% of the company's equity share capital.
Why it mattersA substantial divestment by founding or core promoters signals potential change in control, management restructuring, or significant dilution of promoter alignment with the business.
Jogindersingh Jaswal Stake Sold: 23.09%Jogindersingh Jaswal Shares Sold: 97,96,400Ketan Ramani Stake Sold: 23.09%Pritesh Ramani Stake Sold: 18.09%Pritesh Ramani Shares Sold: 67,11,200
📅 Short termHeavy supply overhang and potential volatility as the market digests substantial insider selling, with attention turning to block deal counterparty details.
📈 Long termSignificantly impacts governance and ownership structure; if taken over by a strategic or institutional investor, strategy execution (like UNIT-IV Dahej expansion) may be influenced by new stakeholders.
⚠ Risk flags
- Massive promoter/insider divestment
- Potential overhang and control uncertainty
Key Highlights
Jogindersingh Jaswal sold 97,96,400 equity shares, representing ~23.09% of paid-up capital
Ketan Ramani sold 97,96,400 equity shares, representing ~23.09% of paid-up capital
Pritesh Ramani sold 67,11,200 equity shares, representing ~18.09% of paid-up capital
Total shares sold across the three disclosures sum to 2,63,04,000 equity shares (~64.27% of capital)
👀 What to Watch
Track subsequent shareholding pattern filings and exchange bulk/block deal disclosures to identify the buyers (whether strategic, institutional, or open-market absorption) and assess potential management control shifts.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax & Chemicals Acquires 64.26% Stake in Kronox Lab; Open Offer Launched for 25.79%
Indo Borax & Chemicals Limited has acquired control of Kronox Lab Sciences Limited after completing the transfer of 2,38,44,000 equity shares (representing 64.26% of paid-up capital) on September 29, 2026. The erstwhile promoters' stake has dropped to 9.95% (36,90,000 shares), and they have applied for re-classification as public shareholders under Regulation 31A. In addition, the acquirer along with Zenrock Chemicals has triggered an open offer to purchase up to 95,70,000 equity shares (25.79% stake) from public shareholders.
Confidence: HIGH
What changedControl of Kronox Lab Sciences has transferred to Indo Borax & Chemicals Limited following the completion of a 64.26% stake purchase.
Why it mattersA complete change of management and promoter group introduces strategic synergies with Indo Borax & Chemicals, potentially altering capital allocation, operations, and governance.
Stake acquired by Acquirer: 64.26%Shares transferred to Acquirer: 2,38,44,000Residual promoter holding: 9.95%Open offer stake size: 25.79%Open offer shares count: 95,70,000
📅 Short termMarket focus will shift towards the open offer pricing, offer timelines, and shareholder tendering process.
📈 Long termThe integration with Indo Borax & Chemicals could unlock commercial synergies in specialty and fine chemicals alongside the operationalization of Unit-IV at Dahej.
⚠ Risk flags
- Integration risks under new controlling ownership
- Open offer execution and acceptance ratios
Key Highlights
Indo Borax & Chemicals completes acquisition of 2,38,44,000 equity shares representing a 64.26% stake
Erstwhile promoters' residual holding declines to 36,90,000 equity shares (9.95%)
Open offer launched to acquire up to 95,70,000 shares, representing 25.79% of the voting share capital
Erstwhile promoters seek reclassification to public category under Regulation 31A(10)
👀 What to Watch
Track the detailed letter of offer and final pricing/tendering schedule for the 25.79% open offer, as well as any strategy updates from the new controlling management.
Indo Borax Acquires 64.26% Stake in Kronox Lab Sciences; Complete Board Overhaul Approved
Kronox Lab Sciences has announced the completion of a major ownership change, with Indo Borax & Chemicals Limited acquiring 2,38,44,000 shares (64.26% stake) from the promoter sellers on September 29, 2026. Following the transaction, the erstwhile promoters retain a 9.95% stake and have stepped down from the promoter group and board positions. In their place, Suresh Kalra has been appointed MD & CEO alongside new executive and independent directors, while outgoing promoters have entered into 36-month transition consultancy agreements valued at ₹2.10 crore each.
Confidence: HIGH
What changedControlling stake (64.26%) transferred from founding promoters to Indo Borax & Chemicals, triggering a total reconstitution of executive leadership and the board.
Why it mattersA complete change in promoters and C-suite leadership brings strategic realignments, operational synergies with Indo Borax, and alters corporate governance dynamics.
Equity shares transferred: 2,38,44,000Acquired stake: 64.26%Retained sellers' stake: 9.95%Consultancy fee per outgoing promoter: ₹2,10,00,000
📅 Short termStock may witness volatility as markets digest the control shift, board overhaul, and potential open offer process.
📈 Long termPerformance will hinge on the incoming management team's ability to maintain high margins and execute ongoing capex such as UNIT-IV Dahej while integrating with Indo Borax.
⚠ Risk flags
- Management transition and integration risks under new ownership
- Related-party consultancy payments to outgoing promoters
Key Highlights
Indo Borax & Chemicals acquired 2,38,44,000 equity shares, representing 64.26% of Kronox's paid-up share capital.
Erstwhile promoters' collective shareholding reduced to 36,90,000 equity shares (9.95%), ceasing their promoter status.
Suresh Kalra appointed Managing Director and CEO for a 5-year term, effective September 29, 2026.
Former promoters Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal resigned from directorships and executive positions.
Key exiting promoters engaged under 36-month transition consultancy agreements with a fixed fee of ₹2.10 crore each.
👀 What to Watch
Track subsequent mandatory open offer disclosures and watch integration updates under the new Indo Borax-backed management, particularly execution progress on the Dahej UNIT-IV expansion.
Indo Borax files DLOF for ₹150.5 Cr Open Offer in Kronox Lab at ₹157.27/share
Kronox Lab Sciences Limited received the Draft Letter of Offer (DLOF) from IIFL Capital Services on behalf of Indo Borax and Chemicals Limited (Acquirer) and Zenrock Chemicals Private Limited (PAC). The open offer is to acquire up to 95,70,000 equity shares, representing 25.79% of the voting share capital (the entire public shareholding). The offer price is set at ₹157.27 per share payable in cash, representing an aggregate consideration of approximately ₹150.51 crore. The tendering period is tentatively scheduled to open on October 15, 2026, and close on October 29, 2026, subject to SEBI comments.
Confidence: HIGH
What changedIndo Borax and Chemicals, along with PAC, submitted the Draft Letter of Offer to SEBI to acquire up to 25.79% of Kronox Lab Sciences.
Why it mattersTriggers a potential change in control or substantial acquisition under SEBI SAST Regulations, giving public shareholders an exit window, though the offer price is currently at a discount to the market price.
Offer Price per share: ₹157.27Shares to be acquired: 95,70,000Offer Size (% of voting capital): 25.79%Tentative Offer Opening Date: October 15, 2026Tentative Offer Closing Date: October 29, 2026
📅 Short termStock may see trading action around the open offer price levels and upcoming regulatory approvals from SEBI.
📈 Long termA change in strategic control or promoter backing by Indo Borax could alter business integration, synergy opportunities, and expansion plans like UNIT-IV.
⚠ Risk flags
- Offer price of ₹157.27 is below the prevailing market price (₹184.70)
- Subject to SEBI review and clearance of the Draft Letter of Offer
Key Highlights
Open offer to acquire up to 95,70,000 equity shares (25.79% voting share capital)
Offer price fixed at ₹157.27 per share in cash
Aggregate open offer consideration amounts to ₹150.51 crore
Tendering period scheduled from October 15, 2026, to October 29, 2026
Independent Directors committee recommendation due by October 13, 2026
👀 What to Watch
Track SEBI comments on the DLOF (tentatively by September 28, 2026) and the Independent Directors Committee's recommendation by October 13, 2026. Note that the offer price of ₹157.27 is below the current market price of ₹184.70.
Indo Borax & Chemicals Issues Detailed Public Statement for Open Offer in Kronox Lab
Indo Borax and Chemicals Limited, along with Person Acting in Concert (PAC) Zenrock Chemicals Private Limited, has published a Detailed Public Statement (DPS) on August 28, 2026, for an Open Offer to acquire equity shares of Kronox Lab Sciences Limited. IIFL Capital Services Limited is acting as the Manager to the Open Offer pursuant to SEBI SAST Regulations. The formal publication was executed across national and regional daily editions on August 28, 2026. This signals a substantial acquisition or potential change in control structure.
Confidence: HIGH
What changedIndo Borax and Chemicals has officially triggered the public announcement phase for acquiring shares in Kronox Lab Sciences.
Why it mattersAn open offer can alter the shareholding pattern, bring new strategic management, or provide an exit window for public shareholders depending on the offer price.
DPS Publication Date: August 28, 2026Promoter Holding: 74.21%Company Net Worth: Rs 116 Cr
📅 Short termThe stock price is likely to trade in close correlation with the open offer price specified in the detailed public statement.
📈 Long termDepending on whether this results in co-promotion or a full change in management, synergies with Indo Borax's chemical operations could shape future business scale.
⚠ Risk flags
- Regulatory approvals required under SEBI Takeover Regulations
- Open offer price vs prevailing market price dynamics
- Uncertainty regarding operational integration post-acquisition
Key Highlights
Open offer initiated by Acquirer Indo Borax and Chemicals Limited along with PAC Zenrock Chemicals Private Limited.
Detailed Public Statement (DPS) officially published in newspapers on August 28, 2026.
IIFL Capital Services Limited appointed as the Manager to the Open Offer.
Company promoter holding stood at 74.21% as of March 2026 ahead of the offer.
👀 What to Watch
Track the upcoming Letter of Offer to evaluate the specific open offer price, total offer size (% of share capital), and the tendering timeline.
Open Offer by Indo Borax & Chemicals to Acquire Shares of Kronox Lab Sciences
Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited as Person Acting in Concert (PAC), has issued a Detailed Public Statement for an open offer to acquire equity shares of Kronox Lab Sciences Limited. The offer is triggered under Regulations 3(1) and 4 of SEBI (SAST) Regulations, 2011, indicating a substantial acquisition and potential change in control. The Detailed Public Statement dated August 27, 2026, was published across national and regional newspapers on August 28, 2026, following the initial Public Announcement dated August 20, 2026.
Confidence: HIGH
What changedIndo Borax and Chemicals has published the Detailed Public Statement to formally proceed with the open offer for acquiring equity shares of Kronox Lab Sciences.
Why it mattersA substantial acquisition or control change under SAST Regulations 3(1) and 4 could alter Kronox's ownership structure, operational direction, and promoter group control.
Detailed Public Statement Date: August 27, 2026Publication Date: August 28, 2026Public Announcement Date: August 20, 2026Current Promoter Holding: 74.21%
📅 Short termMarket focus will center on the open offer pricing compared to current market prices (CMP ₹179.6) and the acceptance ratio for tendering shareholders.
📈 Long termPotential operational synergies or governance changes resulting from integration or partnership with Indo Borax and Chemicals in the specialty fine chemicals space.
⚠ Risk flags
- Regulatory approval contingencies from SEBI for the open offer
- Execution and integration risks depending on final ownership and management control changes
Key Highlights
Open offer initiated by Indo Borax and Chemicals Limited along with PAC Zenrock Chemicals Private Limited
Triggered under SEBI (SAST) Regulations 3(1) and 4 (substantial acquisition and control)
Detailed Public Statement published on August 28, 2026, following initial Public Announcement on August 20, 2026
Offer managed by IIFL Capital Services Limited as Manager to the Offer
👀 What to Watch
Investors should track the upcoming Draft Letter of Offer (DLOF) to review the exact offer price, size, tendering schedule, and management's rationale for the transaction.
Kronox Sets Sept 9, 2026 as Record Date for ₹0.50/Share Final Dividend
Kronox Lab Sciences Limited has fixed Wednesday, September 9, 2026, as the record date for its final dividend of ₹0.50 per equity share (face value ₹10 each) for FY 2025-26. The dividend was previously recommended by the Board on May 21, 2026, and is subject to shareholder approval. Investors holding shares on or prior to the record date will be eligible to receive the dividend payout.
Confidence: HIGH
What changedThe company scheduled the official record date of September 9, 2026, for determining eligibility for the FY26 final dividend.
Why it mattersConfirms the timeline for cash distribution to shareholders following the FY26 dividend recommendation.
Final Dividend per share: ₹0.50Face value: ₹10Record Date: 09-Sep-2026
📅 Short termStock will trade ex-dividend around September 8-9, 2026, with eligible investors receiving the final dividend post-AGM approval.
📈 Long termLimited; this is a standard corporate dividend distribution.
Key Highlights
Final dividend recommended at ₹0.50 per equity share of face value ₹10
Record date fixed for Wednesday, September 09, 2026
Applicable for the financial year ended March 31, 2026
Follows initial recommendation from the Board meeting on May 21, 2026
👀 What to Watch
Track shareholder approval at the upcoming Annual General Meeting and ensure shareholdings are settled before the ex-dividend date to be eligible for the payout.
Indo Borax to Acquire 64.26% Stake in Kronox Lab; Open Offer Launched at ₹157.27/share
Indo Borax and Chemicals Limited, along with PAC Zenrock Chemicals, has executed a Share Purchase Agreement to acquire a controlling 64.26% stake (2,38,44,000 shares) in Kronox Lab Sciences from its promoters at ₹103.22 per share. Following the agreement, an open offer has been announced to acquire up to 95,70,000 shares (25.79% of voting capital) from public shareholders at ₹157.27 per share. The sellers will also provide transition support consultancy services post-closing. IIFL Capital Services is acting as the manager to the offer.
Confidence: HIGH
What changedPromoters of Kronox Lab Sciences agreed to sell 64.26% equity to Indo Borax and Chemicals, triggering a mandatory 25.79% open offer and a change of management control.
Why it mattersA complete shift in promoter ownership and control introduces a new strategic parent in specialty chemicals, potentially impacting strategic priorities such as the Dahej Unit-IV expansion.
SPA Stake Acquired: 64.26%SPA Price per Share: ₹103.22Open Offer Stake: 25.79%Open Offer Price per Share: ₹157.27Open Offer Shares Count: 95,70,000
📅 Short termThe market will digest the open offer price of ₹157.27 per share relative to the prevailing market price of ₹186.20 as the tendering schedule is finalized.
📈 Long termStructural changes will depend on Indo Borax's integration plan, capital allocation strategy, and execution of Kronox's ongoing high-purity chemical expansion at Dahej Unit-IV.
⚠ Risk flags
- Promoter transition and key personnel retention risk post-acquisition
- Open offer price is at a discount to the recent market trading price
Key Highlights
Acquisition of 2,38,44,000 shares (64.26% stake) by Indo Borax & Chemicals at ₹103.22 per share via SPA
Open offer to public shareholders for up to 95,70,000 shares (25.79% voting capital) at ₹157.27 per share
Effective promoter SPA price inclusive of transition consultancy fees is ₹105.87 per share
Key selling promoters include Ketan Ramani, Pritesh Ramani, and Jogindersingh Jaswal
👀 What to Watch
Track the upcoming Detailed Public Statement (DPS), Letter of Offer, and the Kronox Independent Directors' Committee recommendation regarding the ₹157.27 open offer price.
Indo Borax launches ₹150.51 Cr open offer for 25.79% of Kronox Lab Sciences at ₹157.27/share
Indo Borax & Chemicals Ltd, along with Zenrock Chemicals Pvt Ltd, has entered into a Share Purchase Agreement (SPA) to acquire a controlling 64.26% stake (2,38,44,000 shares) from Kronox Lab Sciences' promoters at ₹103.22 per share (effective ₹105.87 including transition consultancy fees). This change of control triggers a mandatory open offer for up to 95,70,000 equity shares (25.79% of voting capital) at an offer price of ₹157.27 per share. The total open offer consideration stands at ₹150.51 Cr payable in cash assuming full acceptance. The acquirer has stated it has no intention to delist the company post-acquisition.
Confidence: HIGH
What changedIndo Borax & Chemicals is acquiring a 64.26% promoter stake in Kronox Lab Sciences, triggering a mandatory 25.79% open offer.
Why it mattersMarks a complete change in promoter ownership and management control, which could alter strategic priorities, capital allocation, and synergies across specialty fine chemicals.
Open Offer Price: ₹157.27Open Offer Size (Shares): 95,70,000Open Offer Stake (%): 25.79%Total Open Offer Value: ₹150,50,73,900SPA Acquisition Stake: 64.26%SPA Price per Share: ₹103.22
📅 Short termMarket trading may reflect the open offer price benchmark of ₹157.27 versus current prevailing trading levels as the timeline towards tendering approaches.
📈 Long termStrategic oversight will transition to Indo Borax & Chemicals, which may impact the timeline and scale of ongoing projects such as the Dahej Unit-IV expansion.
⚠ Risk flags
- Open offer price of ₹157.27 is lower than current trading price (₹186.20)
- Transaction completion is subject to conditions precedent under the SPA
- Transition and integration risks under new promoter management
Key Highlights
Indo Borax & Chemicals to acquire 64.26% stake (2,38,44,000 shares) from existing promoters via SPA at ₹103.22/share
Open offer triggered for 25.79% voting share capital (up to 95,70,000 shares) at ₹157.27 per share
Total open offer cash consideration aggregates to ₹150,50,73,900 (₹150.51 Cr)
Effective SPA price is ₹105.87 per share inclusive of transition support consultancy fees
Acquirers intend to retain the listing status of Kronox Lab Sciences
👀 What to Watch
Monitor upcoming regulatory filings, including the Detailed Public Statement (DPS), Draft Letter of Offer, and fulfillment of conditions precedent governing the change of control.
Indo Borax to acquire 64.26% stake in Kronox Lab Sciences for ₹246.12 Cr; triggers Open Offer
Indo Borax and Chemicals Ltd, along with Zenrock Chemicals, has signed a Share Purchase Agreement (SPA) to acquire a 64.26% stake (2,38,44,000 equity shares) in Kronox Lab Sciences for ₹246.12 crore. The transaction implies an acquisition price of approximately ₹103.22 per share and triggers a mandatory Open Offer for an additional 25.79% stake (up to 95,70,000 shares). Following the transaction, the founding promoters will retain a 9.95% stake and provide transition support, with deal completion expected within 3 months.
Confidence: HIGH
What changedPromoters of Kronox have agreed to sell a controlling 64.26% stake to Indo Borax and Chemicals Ltd, triggering a change in management control and an Open Offer.
Why it mattersThe acquisition transfers controlling interest to a larger specialty chemical player, potentially unlocking product synergies, while the implied deal price and open offer terms are material to current public shareholders.
Stake being acquired via SPA: 64.26%SPA consideration: ₹246.12 croreShares to be acquired via SPA: 2,38,44,000Open Offer size: 25.79% (95,70,000 shares)Promoter residual stake: 9.95%FY26 Revenue reported: ~INR 101 crore
📅 Short termShare price may adjust towards the SPA/Open Offer pricing dynamics, and trading activity will reflect tender offer expectations over the coming weeks.
📈 Long termIf successfully integrated, Indo Borax's scale and boron chemistry expertise combined with Kronox's high-purity chemical portfolio could enhance export reach and margins.
⚠ Risk flags
- SPA consideration (~₹103.22/share) is at a discount to the recent market price (₹172.0)
- Integration and management transition risks under the new promoter
Key Highlights
Indo Borax to acquire 2,38,44,000 shares (64.26% stake) for ₹246.12 crore
Open Offer triggered for up to 95,70,000 shares (25.79% stake) alongside PAC Zenrock Chemicals
Founding promoters to retain a 9.95% stake and provide transition support
Deal completion target is within 3 months from the SPA signing date
Kronox reported FY26 revenue of ~₹101 crore and PAT of ~₹28 crore
👀 What to Watch
Track the detailed public statement for the Open Offer price and timeline, regulatory/statutory approvals, and post-merger integration plans with Indo Borax.
Indo Borax to acquire 64.26% stake in Kronox Lab Sciences at ₹103.22/sh; Open Offer triggered
Kronox Lab Sciences' promoters have entered into a Share Purchase Agreement (SPA) to sell 2,38,44,000 equity shares (64.26% stake) to Indo Borax & Chemicals Limited at ₹103.22 per share (₹105.87 including transition consultancy fees). The deal triggers a mandatory open offer under SEBI Takeover Regulations. Following completion, Indo Borax will take over management control, appointing 3 nominee directors while the current promoter sellers resign and retain a locked-in 9.95% stake.
Confidence: HIGH
What changedPromoters agreed to sell majority control (64.26%) to Indo Borax & Chemicals Ltd at ₹103.22/share, relinquishing board and management control.
Why it mattersA complete change of promoter and management control will alter corporate strategy, capital allocation, and governance, while the SPA price creates short-term valuation benchmarks.
Shares to be Acquired: 2,38,44,000Stake Sold (% of Capital): 64.26%SPA Price per Share: ₹103.22Total Effective Price (incl. fees): ₹105.87Remaining Seller Holding: 9.95%
📅 Short termThe transaction price of ₹103.22–₹105.87 is at a steep discount to the current trading price (~₹172), likely creating near-term downward pressure as the open offer details emerge.
📈 Long termStrategic integration with Indo Borax & Chemicals could drive new synergies, but business execution under the new management team and progress on the Dahej Unit-IV expansion will need monitoring.
⚠ Risk flags
- Steep discount between deal price and prevailing market price
- Management transition risks and change in operational control
- Execution continuity on upcoming capex (Dahej Unit-IV)
Key Highlights
Promoters to sell 2,38,44,000 equity shares (64.26% of paid-up capital) to Indo Borax & Chemicals Ltd
SPA deal price is ₹103.22 per share (₹105.87 including consultancy fees), well below the prevailing market price of ₹172.00
Triggers mandatory SEBI open offer to public shareholders by Indo Borax and PAC (Zenrock Chemicals)
Existing promoters to step down from Board and retain remaining 9.95% stake subject to lock-in and right of first refusal
Acquirer to appoint 3 nominee directors and be reclassified as promoter
👀 What to Watch
Track the detailed public statement (DPS) and draft letter of offer for the open offer price, tendering timeline, and regulatory clearances.
Indo Borax to acquire 64.26% stake in Kronox at ₹103.22/sh; triggers open offer
Promoters of Kronox Lab Sciences have executed a Share Purchase Agreement (SPA) dated August 20, 2026, to sell 2,38,44,000 equity shares (64.26% stake) to Indo Borax & Chemicals Limited and Zenrock Chemicals Private Limited. The transaction price is ₹103.22 per share (₹105.87 per share inclusive of transition consultancy fees), representing a significant discount to the current market price of ₹172.0. Following this transaction, Indo Borax will acquire management control, appoint 3 nominee directors, and make a mandatory open offer to public shareholders.
Confidence: HIGH
What changedPromoters have agreed to sell a controlling 64.26% stake in the company to Indo Borax & Chemicals Limited, stepping down from the board.
Why it mattersThe deal results in a complete change of control and management to Indo Borax, with an impending open offer for public shareholders, though the transaction price is well below the prevailing market price.
Equity shares to be sold: 2,38,44,000Stake being sold: 64.26%SPA price per share: ₹103.22Price including consultancy fees: ₹105.87Remaining promoter stake: 9.95%
📅 Short termThe stock may face downward price discovery pressure given the SPA transaction price of ₹103.22–₹105.87 is sharply lower than the market price of ₹172.0, alongside upcoming open offer details.
📈 Long termStrategic synergies and operational integration with Indo Borax & Chemicals will dictate future growth, capital allocation, and execution on expansion projects like Dahej UNIT-IV.
⚠ Risk flags
- Deal price of ₹103.22 is at a ~40% discount to current market price
- Integration and management transition risk following promoter exit
- Completion subject to customary conditions precedent and regulatory approvals
Key Highlights
Promoters to sell 2,38,44,000 equity shares representing 64.26% stake to Indo Borax & Chemicals Ltd
SPA transaction price set at ₹103.22 per share (₹105.87 per share inclusive of consultancy fee component)
Triggers mandatory open offer under SEBI SAST Regulations to public shareholders
Promoters' remaining 9.95% stake locked in, with promoters resigning from the board and reclassifying as public
👀 What to Watch
Track the detailed public statement (DPS) and draft letter of offer for the open offer, including open offer pricing, timelines, and regulatory approvals.
September 09 Set as Record Date for Final Dividend for FY 2025-26
Kronox Lab Sciences has announced September 09, 2026, as the record date for determining shareholder eligibility for its final dividend for the financial year 2025-26. The dividend payout is contingent upon approval at the 17th Annual General Meeting (AGM) scheduled for September 16, 2026. The company's register of members will remain closed from September 10 to September 16, 2026. This routine corporate action follows a period of strong capital efficiency, with the company reporting a 36.0% ROCE and a minimal debt-to-equity ratio of 0.02.
Confidence: HIGH
What changedThe company has finalized the administrative timeline (record date and book closure) for its FY 2025-26 final dividend distribution.
Why it mattersThis is a routine distribution of profits to shareholders, supported by the company's high purity specialty chemicals business which maintains a strong 36% ROCE.
Record Date: September 09, 2026AGM Date: September 16, 2026Debt-to-Equity Ratio: 0.02ROCE: 36.0%Net Worth: Rs 116 Cr
📅 Short termThe stock may trade with a focus on the dividend yield as the record date approaches, though the specific dividend amount was not detailed in this brief.
📈 Long termLimited; this is a routine procedural filing. Long-term value remains tied to the successful expansion of manufacturing capacity at Dahej.
Key Highlights
Record date for final dividend eligibility is September 09, 2026
17th Annual General Meeting (AGM) to be held on September 16, 2026
Book closure period spans from September 10 to September 16, 2026
Company maintains a low debt of Rs 2 Cr against a net worth of Rs 116 Cr
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date (typically one business day prior to the record date). Monitor the upcoming AGM for updates on the operationalization of the Unit-IV facility at Dahej.
